GlobalData on MSN16d
Viralgen and Axovia to develop gene therapy for retinal dystrophy
Viralgen and Axovia are set to form a partnership to progress the development and manufacturing of gene therapy for retinal ...
ophthalmologytimes6d
Gene therapy voretigene neparvovec boosts vision in pediatric IRD patients
Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated ...
ophthalmologytimes11d
Viralgen and Axovia Therapeutics partner to manufacture gene therapy for Bardet-Biedl Syndrome
The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the ...
Nature15d
Bietti Crystalline Dystrophy And CYP4V2 Gene Mutations
Bietti crystalline dystrophy (BCD) is a rare inherited retinal disease primarily caused by mutations in the CYP4V2 gene. This condition leads to progressive vision loss due to the degeneration of ...
Medindia17d
Viralgen and Axovia partner to manufacture an investigational gene therapy for retinal dystrophy in Bardet-Biedl Syndrome (BBS) patients
Viralgen and Axovia Therapeutics are joining forces to advance the development and manufacture of an AAV9-based inv ...